Related Experiment Videos
[The practical aspects of treatment in heart failure]
C Morisco1, L Argenziano, D Sarno
1Istituto di Medicina Interna, Università degli Studi Federico II di Napoli.
Insights
Congestive heart failure (CHF) treatment is shifting towards a pathophysiological approach. ACE-inhibitors and digitalis can normalize exercise responses in CHF patients, improving cardiac function.
Area of Science:
- Cardiology and Cardiovascular Research
- Clinical Trials and Evidence-Based Medicine
- Pharmacology and Therapeutics
Context:
- Congestive heart failure (CHF) treatment historically relied on empirical methods.
- Major clinical trials have enabled a shift towards a pathophysiological approach in CHF management.
- Dilated cardiomyopathy with mild heart failure (NYHA Class I) exhibits impaired hemodynamic and neurohormonal responses.
Purpose:
- To explore the pathophysiological underpinnings of congestive heart failure.
- To investigate the efficacy of ACE-inhibitors in preventing abnormal responses to volume expansion in CHF patients.
- To evaluate the impact of noninvasive techniques and specific drugs on exercise-induced hemodynamic responses in CHF.
Summary:
- Studies show impaired hemodynamic and neurohormonal responses in mild CHF patients, which ACE-inhibitors can prevent.
- Radionuclide techniques reveal distinct exercise-induced hemodynamic responses in CHF patients compared to healthy individuals.
- Both ACE-inhibitors and digitalis have demonstrated the ability to restore normal exercise-induced hemodynamic responses in CHF patients.
Impact:
- Advances in noninvasive cardiac function assessment enable new pathophysiological insights into CHF treatment.
- Demonstrates the potential of ACE-inhibitors and digitalis to normalize cardiac function during exercise in CHF.
- Supports a targeted, pathophysiological approach to managing congestive heart failure, moving beyond empirical treatments.
Abstract:
Congestive heart failure (CHF) has been treated for several years on empiric basis, until the results of the major clinical trials have made possible a pathophysiological approach to the treatment of patients with CHF. Studies from our laboratories have demonstrated that hemodynamic and neurohormonal responses to acute volume expansion are markedly impaired in patients with dilated cardiomyopathy and mild heart failure (NYHA Class I) and that pretreatment with ACE-inhibitors is able to prevent these abnormal responses. New insights into a more pathophysiological approach to CHF treatment are now possible by the development of new noninvasive techniques for the study of cardiac function. In particular, through radionuclide techniques we were able to demonstrate that patients with CHF show an exercise induced hemodynamic response different from that of normal subjects. Both ACE-inhibitors and digitalis were able to restore a normal response to exercise in patients with CHF.